ACXP

Business Context and Reporting Period

Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics targeting Gram-positive bacterial infections. The company's lead product candidate, ibezapolstat, is in late-stage clinical trials for the treatment of Clostridioides difficile infections (CDI). This summary covers the quarterly period ended September 30, 2025.

The company is classified as an emerging growth company and a smaller reporting company. As of November 11, 2025, there were 2,085,363 shares of common stock issued and outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 28% for the three months ended September 30, 2025, compared to the same period in 2024 ($2.03M vs. $2.83M). This was driven primarily by a 64% decrease in Research and Development (R&D) expenses ($0.43M vs. $1.20M), attributed to lower manufacturing costs and reduced consulting fees related to Phase 2b and Phase 3 preparation.
• Net Loss Improvement: The net loss for the three months ended September 30, 2025, decreased by 29% to $2.0M compared to $2.8M in the prior year period. For the nine-month period, the net loss decreased by 44% to $6.4M from $11.3M.
• Capital Raising: The company significantly increased its cash position through multiple financing activities in the first nine months of 2025, including Registered Direct Offerings in January and March, an Equity Line of Credit (ELOC) with Lincoln Park Capital, and a warrant inducement agreement. Net cash provided by financing activities was $7.8M for the nine months ended September 30, 2025, compared to $6.4M in the prior year.
• Reverse Stock Split: On August 4, 2025, the company effected a 1-for-20 reverse stock split to regain compliance with Nasdaq listing requirements.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: Management states that as of September 30, 2025, the company had approximately $5.9 million in cash. Based on current estimates, this is not sufficient to meet anticipated cash requirements for at least 12 months from the issuance of the financial statements. The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• Financing Needs: The company expects to continue to incur losses and will need additional resources to sustain operations. It plans to seek additional equity financing and grant funding, though there is no assurance such funding will be available.
• Nasdaq Compliance: The company regained compliance with Nasdaq's minimum bid price and minimum stockholders' equity requirements in August 2025 following the reverse stock split and capital raises.
• Key Risks:
  • Dependence on the successful development and regulatory approval of ibezapolstat.
  • Need for substantial additional funding to continue clinical trials and operations.
  • Potential dilution to existing shareholders from future equity issuances.
  • Risks associated with third-party manufacturers and clinical trial execution.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.9 million cash balance against the company's projected burn rate and the timeline for the next financing round.
• Financing Terms: Review the terms of the Equity Line of Credit (ELOC) with Lincoln Park Capital and the warrant inducement agreement for potential dilution and future obligations.
• Clinical Progress: Monitor the status of the Phase 2b clinical trial for ibezapolstat and any updates regarding the initiation of Phase 3 trials.
• Going Concern Status: Assess the impact of the auditor's "substantial doubt" opinion on the company's ability to secure future funding.
• Share Count: Confirm the impact of the 1-for-20 reverse stock split and recent equity issuances on total outstanding shares and per-share ownership.